Michael Breen - GT Biopharma Interim Chairman
| GTBP Stock | USD 2.80 0.24 7.89% |
Insider
Michael Breen is Interim Chairman of GT Biopharma
| Age | 61 |
| Address | 8000 Marina Boulevard, Brisbane, CA, United States, 94005 |
| Phone | 415 919 4040 |
| Web | https://www.gtbiopharma.com |
Michael Breen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Breen against GT Biopharma stock is an integral part of due diligence when investing in GT Biopharma. Michael Breen insider activity provides valuable insight into whether GT Biopharma is net buyers or sellers over its current business cycle. Note, GT Biopharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell GT Biopharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Breen over a year ago Acquisition by Michael Breen of 200000 shares of GT Biopharma subject to Rule 16b-3 | ||
Michael Breen over a year ago Purchase by Michael Breen of 50000 shares of GT Biopharma | ||
Michael Breen over a year ago Acquisition by Michael Breen of 500000 shares of GT Biopharma subject to Rule 16b-3 |
GT Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.6059) % which means that it has lost $0.6059 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3148) %, meaning that it created substantial loss on money invested by shareholders. GT Biopharma's management efficiency ratios could be used to measure how well GT Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/11/2024, Return On Tangible Assets is likely to drop to -0.57. In addition to that, Return On Capital Employed is likely to drop to -1.91. At this time, GT Biopharma's Total Current Liabilities is relatively stable compared to the past year. As of 12/11/2024, Change To Liabilities is likely to grow to about 8.5 M, while Liabilities And Stockholders Equity is likely to drop slightly above 13.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Miles Nunn | Akari Therapeutics PLC | 55 | |
| Alexander Klibanov | Pulmatrix | 74 | |
| Charles Williams | Surrozen | 44 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| MBA CMA | Pulmatrix | 69 | |
| Frank Kondrad | Neurobo Pharmaceuticals | N/A | |
| Karl Hansen | Praxis Precision Medicines | N/A | |
| Dr B | Praxis Precision Medicines | N/A | |
| MBA CMA | SAB Biotherapeutics | 69 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| Ben MD | Neurobo Pharmaceuticals | 68 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Jesse Shefferman | Protara Therapeutics | 52 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| MBA MD | Surrozen | 56 | |
| Kristine Rosse | Protara Therapeutics | N/A | |
| MBA CFA | Vaccinex | 50 | |
| Kelly McCue | Praxis Precision Medicines | N/A | |
Management Performance
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.61 |
GT Biopharma Leadership Team
Elected by the shareholders, the GT Biopharma's board of directors comprises two types of representatives: GT Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GTBP. The board's role is to monitor GT Biopharma's management team and ensure that shareholders' interests are well served. GT Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GT Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Breen, Interim Chairman | ||
| Manu Ohri, Chief Officer | ||
| Jeffrey MD, Consulting Advisor | ||
| Gregory MD, Chief RD | ||
| MPH MBA, VP Management | ||
| PharmD MBA, Chief Officer | ||
| Alan CPA, Chief Officer |
GTBP Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GT Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | (4.03 M) | ||||
| Shares Outstanding | 2.23 M | ||||
| Shares Owned By Insiders | 12.14 % | ||||
| Shares Owned By Institutions | 67.52 % | ||||
| Number Of Shares Shorted | 19.41 K | ||||
| Price To Book | 2.74 X | ||||
| EBITDA | 5.98 M | ||||
| Net Income | (7.6 M) |
Pair Trading with GT Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against GTBP Stock
| 0.85 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.74 | LLY | Eli Lilly | PairCorr |
| 0.71 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.62 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.51 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.